Email Updates

You are here

Webinar & Meeting Reports

  • December 2, 2019 to December 7, 2019

    The 20th International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA 2019) was December 2-7 in Kigali, Rwanda. Find details below on select events of interest. AVAC was there along with many of our partners and participated in sessions both before and during the conference.

  • December 1, 2019

    World AIDS Day takes place on 1 December every year. It’s an opportunity for everyone to support people living with HIV/AIDS, commemorate those we have lost, take stock of the tireless work being done worldwide and re-energize advocacy efforts to end the epidemic.

  • November 13, 2019

    The FDA’s October approval excluded F/TAF as PrEP “for those who have receptive vaginal sex.” Many voices have expressed outrage that Gilead’s strategy for F/TAF regulatory approval left women by the wayside. Gilead had previously claimed finding a relevant cohort of women would not be feasible. Gilead is designing a novel trial, planned to begin in Africa in 2020, to gather missing data about the safety and efficacy of F/TAF among cisgender women. What are the implications of this trial?

  • November 11, 2019

    Advocates, policy makers, funders and other stakeholders have surfaced a number of questions regarding Descovy (F/TAF) for PrEP – recently approved by the FDA to prevent HIV during anal sex. With Truvada (TDF/FTC) set to go off patent next year, several generic options waiting in the wings, and our community’s reliance on the 340B program for funding PrEP-related services, many have raised concerns about price, policy and programming related to Descovy.

  • October 22, 2019

    Two things need to happen to achieve greater success in the global fight against HIV: dramatically reduce new infections and achieve viral suppression in those already living with the virus. In order to meet these goals, new infections must come down from an annual rate of 1.7-2 million that has been stagnant for a decade, viral suppression must be sustained and ensured for the more than 23 million people living with HIV (PLHIV) on anti-retroviral treatment (ART), and treatment must be provided to the more than 14 million PLHIV not on ART.

  • October 7, 2019

    Please join AVAC, the Treatment Action Group (TAG), The Well Project and the Women’s Research Initiative (WRI) on Monday, October 7 at 9-10am ET for an Advocates’ Debrief on the Science of Daily F/TAF vs. TDF/FTC as PrEP.

  • September 5, 2019 to September 8, 2019

    The 2019 United States Conference on AIDS (USCA) is returning to Washington, DC on September 5-8 at the Marriott Marquis Hotel. This year the focus will be on the plan to end the HIV epidemic in America. The conference will be an opportunity for health departments, community-based organizations, People Living with HIV, People on PrEP, national organizations, health centers, health care providers, donors, activists, and federal leaders to come together to discuss implementation.

  • August 22, 2019

    On August 22 the Fellows team held the 2020 AVAC Fellows Global Info Session. AVAC’s Advocacy Fellows Program launched in 2009 to expand the capacity of advocates and organizations to accelerate, shape and monitor biomedical HIV prevention research and implementation worldwide. Since the start, seventy Fellows have moved through the program in its first 10 years, many of whom have gone on to become leaders in the HIV movement in their communities, countries and globally.

  • July 21, 2019 to July 24, 2019

    The IAS 2019 conference is a biennial gathering for those working in the field of HIV, including policy makers, persons living with HIV and other individuals committed to ending the epidemic, was held in Mexico City, Mexico. It featured some of the most critical advances in basic, clinical and operational research that moves science into policy and practice.

  • June 27, 2019

    On Thursday, June 27, women and our allies, participated in an interactive discussion about what the post-ECHO trial agenda for contraception and HIV should look like. This critical call aimed to help inform civil society advocates agenda for an upcoming WHO meeting on this subject. The leaders of the Civil Society Working Group on HC-HIV, members of the ECHO Global Community Advisory Group and young women advocates joined for this discussion with WHO and ECHO management team members.

Pages